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1804Early and Late Extensive Chronic Graft-versus-Host
Disease in Children Is Characterized by Different
Th1/Th2 Cytokine Profiles: Findings of the Children’s
Oncology Group Study ASCT0031
Jacob Rozmus,1 Kirk R. Schultz,1,2 KristinWynne,1 Amina Kariminia,1 Preeti Satyanarayana,3
Mark Krailo,4 Stephan A. Grupp,5 Andrew L. Gilman,6 Frederick D. Goldman7Numerous mechanisms underlie chronic graft-versus-host disease (cGVHD), including skewing of Th1/Th2
cytokine expression. There are biological differences between early-onset and late-onset cGVHD. To test
whether different Th1/Th2 cytokines are associated with early- or late-onset cGVHD, peripheral blood
was collected from 63 children enrolled on the Children’s Oncology Group Phase III trial ASCT0031 eval-
uating hydroxychloroquine therapy for newly diagnosed extensive cGVHD. mRNA expression of interferon
(IFN)-g and interleukin (IL)-2, -4, and -10 from stimulated peripheral blood mononuclear cells was evaluated
by quantitative polymerase chain reaction. Early-onset cGVHD (n5 33) was characterized by decreased ex-
pression of IFN-g and IL-2 mRNA after nonspecific phorbol 12-myristate 13-acetate–ionomycin stimulation.
In contrast, late-onset cGVHD (n5 11) was characterized by decreased expression of IL-4 and IL-2 mRNA
after anti-CD3 stimulation of T cells. Receiver-operating characteristic curve analysis revealed that IFN-g
expression was correlated with the absence of early cGVHD (area under the curve [AUC] 5 0.77) and
that IL-4 (AUC5 0.89) and IL-2 (AUC5 0.84) expression was correlated with the absence of late cGVHD.
There was no correlation between cytokine expression and a specific immune cell subset. Increased expres-
sion of Foxp3 mRNA was seen in early-onset cGVHD and late controls. The different time-dependent
cytokine profiles in patients with newly diagnosed cGVHD suggests that the mechanisms underlying cGVHD
are temporally regulated. Although larger validation studies are needed, our data suggest that cytokine
profiles have a potential use as biomarkers for the diagnosis of cGVHD.
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Myeloablative allogeneic blood and marrow trans-
plantation (BMT) is the only successful cellular-based
immunotherapy for high-risk hematopoietic malig-
nancies. It also is the only curative treatment for
numerous marrow failure syndromes [1], nonmalig-
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related donors, more than one-half of patients who
receive an allogeneic BMT will develop chronic
graft-versus-host disease (cGVHD) [6], which has be-
come the leading cause of transplantation-relatedmor-
bidity and mortality [7]. In adults with cGVHD,
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merous possible mechanisms of cGVHDhave been in-
vestigated, but previous human clinical studies have
been hindered by a number of factors, including (1)
the insidious onset and multiple organ involvement
of cGVHD, (2) samples obtained at different times
in the course of the disease and from patients taking
a wide variety of immunosuppressants, (3) failure to
consider time of onset, and (4) lack of proper controls
to account for patterns of normal immune recovery
post-BMT.
Our group previously reported evidence suggest-
ing that the biology of cGVHD is temporally different
and influenced by immune reconstitution after BMT,
and that there are different patterns of biomarkers in
early-onset (3-8 months post-BMT) and late-onset
($9 months post-BMT) cGVHD [10]. Soluble B cell
activation factor (sBAFF), anti-dsDNA antibody, solu-
ble interleukin -2 receptor a (sIL-2Ra), and soluble
CD13 (sCD13) were elevated in patients with early-
onset cGVHD compared with controls. sBAFF and
anti-dsDNA were elevated in patients with late-onset
cGVHD. These previous findings suggest that the
pathophysiology of cGVHD is heterogeneous, with
different mechanisms operative at different times after
BMT. The present study aimed to further characterize
the differences between early-onset and late-onset
cGVHD.
A number of different effector cell types are
thought to be important in the pathophysiology of
cGVHD, including B cells, regulatory T (Treg) cells,
and effector and memory T cells. B cells have been in-
creasingly recognized as having an important role in the
pathophysiology of cGVHD, as was initially identified
in amurinemodel by our group [11]. Later human data
confirmed the importance of B cells in cGVHD by
establishing a role for autoantibodies, such as HY
antibodies inmale recipients with female donors corre-
lating with cGVHD development [12-14], high levels
of sBAFF [10,15], increased plasma cell populations
[16], and CD21–CD271 B cells [17]. Their importance
also is clinically supported by the successful treatment
of steroid-refractory cGVHD with rituximab, an anti-
CD20 (B cell antigen) monoclonal antibody [18-20].
The role of Tregs in cGVHD is less clear. Mouse
models show that Tregs play an important role in pre-
vention of GVHD [21], and that adoptive transfer of
freshly isolated or ex vivo expanded CD41CD251
T cells can prevent GVHD [22,23]. In humans, there
are conflicting data as to the importance of Tregs in
cGVHD, with different studies showing decreased,
unchanged, or increased numbers of these regulatory
cells [24-27].
The roles of other T cell populations appear to be
equally varied and unclear. cGVHD has been
associated with a preponderance of interferon
(IFN)-g–, IL-4–, IL-5–, and IL-2–producing CD41effector memory cells [28,29] and with infiltration of
CD81 T cells in skin [30] and intestine [31]. OX40,
an activation marker on both CD41 and CD81 T cell
populations, may be associated with cGVHD onset
[32]. A predominance of cytokine-producing Th1/
Th2 immune responses has also been postulated. A re-
view of the current literature yields contradictory re-
sults regarding the synthesis of cytokines, such as
IFN-g. In some studies, increased IFN-g mRNA ex-
pression has been associated with extensive cGVHD
[33,34], whereas others have shown that patients with
microsatellite polymorphisms within the first intron
of the IFN-g gene associated with decreased
production have higher rates of cGVHD [35]. In
mousemodels, high IFN-gproduction by natural killer
(NK) T cells results in lower rates of cGVHD [36,37].
There are no data on this mechanism in children.
Based on our findings showing different biomarker
profiles in early-onset and late-onset cGVHD, we hy-
pothesized that distinctive Th1/Th2 cytokine profiles
are associated with early and late cGVHD. To verify
our hypothesis, we made use of a well-controlled Chil-
dren’s Oncology Group study, ASCT0031, evaluating
hydroxychloroquine therapy in children with newly di-
agnosed extensive cGVHD between 2002 and 2005.
As part of the biological studies associated with this
clinical trial, we prospectively measured mRNA levels
of IFN-g, IL-2, IL-4, and IL-10 in peripheral blood
mononuclear cells (PBMCs) after either nonspecific
mitogen stimulation with phorbol 12-myristate 13-
acetate (PMA)-ionomycin (PI) or T cell stimulation
with anti-CD3 in newly diagnosed cGVHD patients
and comparing these levels with those in time-
matched BMT control subjects who did not develop
cGVHD. We also collected data on the percentage
and absolute counts of immune cell subsets, and retro-
spectively analyzed mRNA levels of Foxp3 in resting
or anti-CD3–stimulated PBMCs to investigate the
temporal role of regulatory T cells in cGHVD.PATIENTS AND METHODS
Patients
Samples were obtained from patients enrolled in
the Children’s Oncology Group trial ASCT0031. All
enrolled patients provided signed informed consent
approved by each individual center’s Institutional
Review Board in accordance with the Declaration
of Helsinki. The study was a Phase III randomized,
placebo-controlled, double-blinded trial evaluating
2 treatment regimens for patients age 1-30 years
with newly diagnosed extensive cGVHD. The
patients received a standard regimen of cyclosporine
and alternate-day prednisone with either hydroxy-
chloroquine or placebo. Eligibility requirements
allowed concurrent steroid therapy for treatment
1806 Biol Blood Marrow Transplant 17:1804-1813, 2011J. Rozmus et al.and/or prophylaxis of acute GVHD (aGVHD) if the
prednisone dose was #2 mg/kg/day (or equivalent) at
study entry. Enrollment was entirely voluntary at
each center, and there was no attempt to establish
matched controls for the patients with cGVHD.
The decision to allow a center to participate in con-
trol enrollment was based not on the characteristics
of the patients enrolled, but rather on the resources
available to identify and follow such individuals.
Newly diagnosed extensive cGVHD was docu-
mented with biopsy confirmation of at least one
organ system (eg, lip, skin, liver) and either general-
ized skin involvement or localized skin involvement
and/or liver dysfunction plus at least one of the fol-
lowing: liver histology showing chronic aggressive
hepatitis, bridging necrosis, or cirrhosis; eye involve-
ment (Schirmer’s test with\5 mm wetting); involve-
ment of minor salivary glands or oral mucosa on lip
biopsy; or involvement of any other target organs or
of at least 2 target organs. Peripheral blood samples
in patients with cGVHD were collected at study en-
try and at 2 months, 6 months, and 12 months after
study entry. For controls, peripheral blood was col-
lected from patients without documented cGVHD
at 6 and 12 months after transplantation. A total of
82 patients were enrolled in the original Phase III
trial. Forty-four patients with cGVHD and 19
control patients without cGVHD were included
in this part of the study for a total of 63 patients,Table 1. Comparison of Patients with cGVHD and Controls for D
GVHD Prophylaxis, and Concurrent Steroid Therapy
Early Controls
(n 5 18)
Early c
(n 5
Age, years
Median (range) 9.0 (1.3-20.7) 11.3 (2
Mean ± standard deviation 9.7 ± 6.0 12.0
Sex, n (%)
Male 12 (67) 23 (7
Female 6 (33) 10 (3
Donor source, n (%)
Bone marrow 11 (61) 13 (3
Peripheral blood 4 (22) 14 (4
Umbilical cord blood 3 (17) 6 (1
Donor type, n (%)
Sibling 13 (72) 15 (4
Unrelated 5 (28) 18 (5
aGVHD, n (%)
Yes 6 (33) 20 (6
No 12 (66) 13 (3
GVHD prophylaxis, n (%)
Cyclosporine 14 (78) 26 (7
Methotrexate 13 (72) 22 (6
Steroids 6 (33) 8 (2
Tacrolimus 6 (33) 7 (2
Mycophenolate mofetil — 2 (6
Antithymocyte globulin — 2 (6
On prednisone or equivalent (#2 mg/kg/day)
at study entry
Yes 8 (44) 16 (4
No 10 (56) 17 (4
CI indicates confidence interval.representing 77% of the original sample size. The
samples collected were used for a number of different
studies, and the present study was limited by the
amount of sample received for some patients. Con-
trol samples were collected at 6 months and 12
months post-BMT from patients without cGVHD
to address the potential confounding factor of im-
mune reconstitution after BMT. A time-matched
comparison was performed, with days post-BMT at
the time of cGVHD diagnosis used to divide the pa-
tients into an early-onset group (3-8 months) and
a late-onset group ($9 months) to allow comparison
with samples from control patients drawn at 6
months and 12 months post-BMT, respectively. All
blood samples were collected before initiation of
protocol therapy.Patient Characteristics
Patients with cGVHD and controls at each time
point were compared for differences in age, sex, donor
source, donor type, aGVHD,GVHDprophylaxis, and
concurrent steroid use (#2 mg/kg/day) (Table 1).
There appeared to be a clinical difference in unrelated
donors, peripheral blood source, and aGVHD at the
early time point, as expected given that all are associ-
ated with higher rates of cGVHD, but there was no
apparent statistically significant difference between
the groups at each time point.ifferences in Age, Sex, Donor Type, Donor Source, aGVHD,
GVHD
33)
Difference
(95% CI)
Late Controls
(n 5 11)
Late cGVHD
(n 5 11)
.0-21.0) 7.3 (1.2-15.4) 13.5 (3.2-21.8)
± 5.7 7.0 ± 4.8 13.2 ± 5.5
0) 7 (64) 8 (73)
0) 4 (36) 3 (27)
9) 21.7% (-6 to 49) 7 (64) 7 (64)
2) 20.2% (-45 to 5) 2 (18) 2 (18)
8) 2 (18) 2 (18)
5) 27% (0-54) 7 (64) 5 (45)
5) 27% (-53 to 0) 4 (36) 6 (55)
1) 27% (-54 to 0) 4 (36) 6 (55)
9) 27% (0-54) 7 (64) 5 (45)
9) 10 (91) 9 (82)
7) 8 (73) 6 (55)
4) 4 (36) 3 (27)
1) 3 (27) 2 (18)
) — —
) — —
8) 5 (45) 3 (27)
8) 6 (55) 8 (73)
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Th1 (IL-2 and IFN-g) cytokine, Th2 (IL-4 and IL-
10) cytokine, and Foxp3 mRNA levels were determined
byquantitativepolymerase chain reaction (qPCR).Blood
from cGVHD and control subjects was collected in hep-
arinized tubes and then shipped overnight at room
temperature to the reference laboratory at theUniversity
of Iowa. PBMC (0.5-1.0  106), isolated by Ficoll-
Hypaque separation, were maintained in complete
RPMImedium (10% fetal calf serum, 1000 U/mL peni-
cillin, 1000U/mL streptomycin, and 20mMglutamine),
then placed in Costar plates with medium alone or stim-
ulated with PMA (75 ng/mL; Sigma-Aldrich, St. Louis
MO) plus ionomycin (1 mM, Sigma-Aldrich) or with
plate-bound anti-CD3 (biotinylated anti-CD3; Phar-
mingen, San Diego, CA). After an 18-hour incubation,
cells were lysed and RNA was isolated with the Qiagen
RNeasy Mini Kit (Qiagen, Valencia, CA). cDNA was
generated using theGibcoBRLSuperscript First-Strand
Synthesis system (Invitrogen, Carlsbad, CA). qPCR was
performed according to the manufacturer’s instructions
asdescribedpreviously [38].TaqManprimers andprobes
for human cytokines were purchased from Applied Bio-
systems (Foster City, CA), and samples were analyzed
using the ABI Prism 7700 Sequence Detection System
(Applied Biosystems). For each sample, mRNA expres-
sion level was normalized to the level of glyceralde-
hyde-3-phosphate dehydrogenase housekeeping genes.
Thevalueof each samplewasanaverageof3 independent
qPCRmeasurements. Data from the qPCR experiments
were analyzed using the comparative CT method for
multiplex reactions, as described previously [39].
Flow Cytometric Analysis of Immune Cell
Populations
PBMCs were isolated by Ficoll-Hypaque gradient
centrifugation. After isolation, cells were washed twice
in FACS staining buffer (phosphate-buffered saline,
0.1% sodium azide, 1% fetal calf serum), and then
stained with a panel of fluorescein-conjugated anti-
bodies. Expression of cell surface markers was quanti-
fied with a FACScan analyzer (BD Biosciences
Immunocytometry Systems, San Jose, CA) and
Cellquest V3.2 software (BD Biosciences, Mountain
View, CA), as described previously [40]. Mouse anti-
human monoclonal antibodies (mAbs), conjugated
with fluorescein isothiocyanate, phycoerythrin, or
peridinin chlorophyll protein complex and reacting
with T cell markers (CD3, CD4, and CD8), B cell
markers (CD19), NK cell markers (CD16/56), and
various other markers (ie, CD25, CD57, CD69,
HLA-DR), were purchased from BD Biosciences.
Statistical Analysis
Descriptive statistics for all data were generated
using Prism version 4 (GraphPad Software, San Diego,CA). The percentage change in cell surface molecule ex-
pression was defined as the difference in the percentage
of positive cells after culture with stimulation and the
percentage of positive cells after culture in otherwise
identical conditions with no stimulation. The degree of
dispersion from the mean was calculated as standard
deviation (s). The significance of observed changes was
determined using the Mann-Whitney U test. The a (P)
value was set at .05, making all P values\.05 statistically
significant. Even when a P value was\.05, the results
were not considered biologically significant unless the
difference was either 50% higher or lower in the
GVHD value compared with the control value. The
receiver-operating characteristic (ROC) curve method-
ologywas used to assess the ability of cytokine expression
to predict the likelihood of cGVHD. The ability to dis-
criminate between the presence and absence of cGVHD
was evaluated using the area under the ROC curve
(AUC). An AUC value of 0.5 indicates that themeasure-
ment is no better than chance in discriminating between
the 2 conditions, whereas a value of 1 indicates perfect
discriminatory power.ROCanalysis allowed us to deter-
mine cutoffs for cytokine levels to maximize accuracy.RESULTS
IFN-g, IL-4, IL-2, and IL-10 Concentrations
in Early Chronic GVHD
We evaluated cytokine mRNA expression from
PBMCs after activation with a nonspecific mitogen,
PI, which stimulates all T cells, NK cells, monocytes,
and B cells, and compared these findings with cytokine
expression after T cell–specific stimulation with anti-
CD3 mAb. We found decreased IFN-g production
in patients with early cGVHD compared with early
controls after PI stimulation (Figure 1A; P 5 .002),
but no difference in IFN-g production after anti-
CD3 mAb stimulation (Figure 1B). Similarly, we
found decreased IL-2 production in patients with early
cGVHD versus early controls after PI stimulation
(Figure 1C; P5 .03), but no significant difference after
anti-CD3 mAb stimulation. No differences were seen
for either PI or anti-CD3 mAb-stimulated IL-4 pro-
duction in early cGVHD (Figure 1E and F). IL-10
production was assessed only after anti-CD3 mAb
stimulation. There appeared to be a higher expression
in patients with early cGVHD, but the difference was
not statistically significant (Figure 1G; P 5 .12). A
previous history of aGVHDwas not significantly asso-
ciated with the expression of any cytokine.IFN-g, IL-4, IL-2, and IL-10 Concentrations in
Late cGVHD
Neither PI nor anti-CD3 mAb stimulation
resulted in a significant difference in IFN-g expression
Figure 1. (A) IFN-gmRNA production at early and late time points in controls and patients with cGVHD after PI stimulation for 18 hours. (B) IFN-gmRNA
production at early and late time points in controls and patients with cGVHD after anti-CD3mAb stimulation for 18 hours. (C) IL-2mRNAproduction at early
and late timepoints in controls andpatientswith cGVHDafterPI stimulation for18hours. (D) IL-2mRNAproductionatearly and late timepoints in controlsand
patientswith cGVHDafter anti-CD3mAbstimulation for18hours. (E) IL-4mRNAproduction at early and late timepoints in controls andpatientswith cGVHD
afterPI stimulation for18hours. (F) IL-4mRNAproductionatearly and late timepoints in controls andpatientswith cGVHDafter anti-CD3mAbstimulation for
18 hours. (G) IL-10 mRNA production at early and late time points in controls and patients with cGVHD after anti-CD3 mAb stimulation for 18 hours.
1808 Biol Blood Marrow Transplant 17:1804-1813, 2011J. Rozmus et al.
Figure 2. (A) ROC curve analysis of IFN-g mRNA production after PI
stimulation for predicting the absence of early cGVHD. (B) ROC curve
analysis of IL-2 mRNA production after anti-CD3 stimulation for pre-
dicting the absence of late cGVHD. (C) ROC curve analysis of IL-4
mRNAproduction after anti-CD3 stimulation for predicting the absence
of late cGVHD.
Biol Blood Marrow Transplant 17:1804-1813, 2011 1809Cytokine Expression in Chronic GVHDin patients with late-onset cGVHD versus controls
(Figure 1A and B). IL-2 production, which was lower
in patients with late-onset cGVHD versus late con-
trols after PI stimulation, became significant only after
stimulation with anti-CD3 mAb (Figure 1D; P 5
.007). Similarly, there was decreased IL-4 production
after PI stimulation in patients with late cGVHD ver-
sus late controls (Figure 1E; P5 .07), although the dif-
ference was not statistically significant. This difference
became significant after T cell–specific anti-CD3mAb
stimulation (Figure 1F; P 5 .004). IL-10 production
was assessed only after anti-CD3mAb stimulation. Ex-
pression appeared to be higher in patients with late
cGVHD, but again the difference was not statistically
significant (Figure 1G; P 5 .10). A previous history of
aGVHDwas not associated with a significant effect on
expression of any cytokine.
ROC Analysis of Cytokine Levels to Predict the
Absence of cGVHD
We used ROC curve analyses to explore whether
and if so, at what level, cytokine mRNAs might be use-
ful in predicting the presence or absence of cGVHD.
PI-induced IFN-g production was found to be poten-
tially useful in predicting the absence of GVHD at
the early time point, with an AUC value of 0.77
(Figure 2A; P 5 .002), with 80% specificity at a value
of 20,544 (sensitivity, 73%). Analysis of PI-induced
IL-2 production at the early time point did not yield
a sufficiently high AUC value to be predictive
(AUC5 0.69; P5 .03). We found no significant asso-
ciation for either IFN-g (AUC5 0.62; P5 .18) or IL-2
(AUC5 0.57; P5 .40) after T cell–specific stimulation
with anti-CD3mAb. IL-4had nopredictive value at the
early time point.
At the late time point, ROC analysis revealed
a strong predictive value for the absence of cGVHD
of anti-CD3–induced IL-4 production (Figure 2B;
AUC5 0.89; P5 .004), with 80% specificity at a value
of 170.5 (sensitivity, 91%), as well as IL-2 production
(Figure 2C; AUC 5 0.84; P 5 .006), with 80% speci-
ficity at a value of 189.5 (sensitivity, 82%) in the late
cGVHD population. PI-induced IL-4 production
(AUC5 0.74; P5 .06) was not significantly predictive
of the absence of late cGVHD. Contrary to the early
cGVHD group, the significant IL-2 results seen in
the late cGVHD group were obtained only wht
T cell–specific anti-CD3 mAb stimulation..
Evaluation of Other Factors That May Affect
Cytokine Production
The cytokine patterns in early-onset and late-onset
cGVHD were not correlated with the donor type
(related or unrelated), graft source (cord blood,
peripheral blood, or bone marrow), or organ involve-
ment by cGVHD (data not shown).Foxp3 mRNA Concentrations in Early-Onset
and Late-Onset Chronic GVHD
At the time of our retrospective analysis, no consis-
tent Foxp3 antibody was available for flow cytometry;
thus, we measured mRNA expression in unstimulated
and anti-CD3 stimulated PBMC samples. We found
a nearly 10-fold increase in Foxp3 mRNA expression
in patients with early-onset cGVHD, although the dif-
ference did not reach statistical significance in either
the unstimulated (Figure 3A; P 5 0.08) or anti-
CD3–stimulated (Figure 3B; P5 .27) sets. Conversely,
at the later time point, there was an increase in Foxp3
mRNA expression in control patients that was
1810 Biol Blood Marrow Transplant 17:1804-1813, 2011J. Rozmus et al.significant in the anti-CD3–stimulated set (Figure 3B;
P 5 .04).
Absolute Lymphocyte Count and Correlation of
Immune Cell Subsets with Cytokine Production
We measured the absolute lymphocyte count
(ALC) at the early and late time points for all 4 combi-
nations of aGVHD (A) and cGVHD (C): A–C–, A1C–,
A–C1, and A1C1. At the early time point, the highest
ALC was in the A1C1 group, with 2339 6 3245/mL,
followed by A–C1 with 2141 6 1280/mL, A1C– with
1586 6 1122/mL, and A–C– with 1144 6 477/mL.
There was a statistically significant difference between
the patients with cGVHDandwithout cGVHDandno
history of aGVHD (P 5 .009). There were no signifi-
cant differences between groups at the late time point
(A–C–, 2013 6 1669/mL; A1C–, 2312 6 1402/mL;
A–C1, 2274 6 3055/mL; and A1C1, 2729 6 2174/Figure 3. (A) Foxp3 production at early and late time points in controls
and patients with cGVHD in unstimulated samples. (B) Foxp3 produc-
tion at early and late time points in controls and patients with cGVHD
after anti-CD3 mAb stimulation for 18 hours.mL). There also were no statistically significant differ-
ences in the percentages of cell phenotypes—T cells
(CD31, CD41, CD41CD571, CD81, CD81CD571),
NK cells (CD3–CD161CD561), and B cells
(CD191)—in patients with cGVHD and controls at
both time points in unstimulated samples. We also
compared the percentages of activated T cell lym-
phocyte subsets (CD41CD251, CD81CD251,
CD41CD691, CD81CD691, CD41HLA-DR1, and
CD81HLA-DR1) in unstimulated versus anti-CD3–
stimulated samples and found no significant differ-
ences. Furthermore, we found no correlation between
mRNA expression of all cytokines and the percentage
and absolute cell counts of anti-CD3–stimulated T
cell lymphocytes evaluated at both time points (data
not shown).DISCUSSION
One of the most significant findings from the pre-
viously published Children’s Oncology Group
ASCT0031 study is that there are immunologic differ-
ences between cGVHDoccurring early after BMT (3-8
months) and that occurring later ($9months) [10], and
that immune reconstitution post-BMT can signifi-
cantly affect the interpretation of cGVHD biomarkers.
In the current analysis, the presence of early cGVHD
was characterized by a decreased Th1 cytokine
mRNA response, whereas the presence of late cGVHD
was characterized by a decreased Th2 cytokine mRNA
profile. Despite our small number of patients, we found
significant patterns that require subsequent validation
in larger prospective clinical trials.
To better understand the immunopathogenesis of
cGVHD, PBMCs isolated from patients with new-
onset cGVHD and time-matched controls were stim-
ulated with a nonspecific lymphocyte mitogen, PI, or
T cell–specific anti-CD3 mAb. In patients with
early-onset cGVHD, IFN-g and IL-2 mRNA expres-
sion was significantly decreased only after PI stimula-
tion, and not after anti-CD3 mAb stimulation,
suggesting that the initial effector cell populations
might not be T cells. One possibility is that these effec-
tors are NK cells, which are capable of producing in-
flammatory cytokines and mediating cytolytic activity
[41]. The concept of anNK-mediated regulatory func-
tion is supported by the observation that a higher num-
ber of bone marrow NK cells is associated with
a decreased incidence of cGVHD after HLA-
identical sibling bone marrow transplantation in hu-
mans [42]. Recent findings indicate that this regulatory
function can be mediated through dendritic cells
(DCs). Through the production of IFN-g, NK cells
can enhance the function of DCs, induce expression
of costimulatory molecules and production of IL-12
and TNF-a, and skew the T cell stimulatory capacity
Biol Blood Marrow Transplant 17:1804-1813, 2011 1811Cytokine Expression in Chronic GVHDof DCs toward Th1-type responses. It has been sug-
gested that NK cells mediate reduction of cGVHD
by direct lysis of T cells, inhibition of donorT cell pro-
liferation, and induction of T cell apoptosis [43].
There is much less evidence suggesting a protective
role for B cells in cGVHD.EffectorB cells (Be1 andBe2
cells) can secrete cytokines, such as IFN-g,
IL-12, IL-4, and IL-2, that reinforce and stabilize the cy-
tokine profiles of both effector Th1 and Th2 cells [44].
Our findings suggest that the ability to generate
a Th1/Tc1 response (IFN-g and IL-2) early post-
BMT protects against cGVHD. Unfortunately, we did
not find any correlation between IFN-g and IL-2
mRNA expression and the number of NK or B cells. A
limitation of the present study was the lack of functional
studies on immune cell subsets. It will be important in
future trials to determine which immune cells are re-
sponsible for the production of our cytokines of interest.
The decreased IL-4 mRNA expression in patients
with late-onset cGVHD supports the widely accepted
hypothesis that aTh2 response is protective. In contrast
to the earlier time point, there was significant elevation
with both PI- and anti-CD3–induced IL-4 production,
suggesting that the effector cell population may be
a CD31 T cell population. One promising candidate
is the Tregs, as described previously [21-23]. We also
observed a significant decrease in IL-2mRNAsynthesis
in patients with early-onset and late-onset cGVHD.
IL-2 is known to play a central role in Th2 differentia-
tion [45], and is reportedly necessary for the production
and expansion of CD41CD251 Tregs [46]. Mice defi-
cient in either IL-2 or elements of its receptor develop
a massive lymphoproliferative syndrome accompanied
by severe autoimmunity [47,48]. IL-2 is necessary for
B cell tolerance, and its absence could contribute to
the unchecked expansion of autoreactive B cells. A
role for B cells in the pathophysiology of cGVHD has
been suggested, and as part of this study we identified
increased numbers of B cells, primed for a Toll-like re-
ceptor 9 (TLR9) response [49]. However, we did not
find a difference in the absoluteCD191B cell count be-
tween control andGVHD patients, although our study
was limited by the lack of specific phenotype labeling
(such as IgM memory B cells [50] or CD21– B cells
[17]) and functional data.
To better address the potential role of regulatory
T cells in cGVHD, we retrospectively measured
Foxp3 mRNA expression from archived frozen cell ly-
sates. During the initial design of the study, a proper
Foxp3 antibody was not available, and data on this
cell type were limited. At the early time point, we
were able to show a trend toward increased Foxp3
mRNA expression in anti-CD3–stimulated cell lysates
from patients with cGVHD. In contrast, at the late
time point, we found an increase in Foxp3 mRNA
expression in anti-CD3–stimulated cell lysates from
patients without cGVHD. Although these resultswere not statistically significant, they could suggest
the presence of different activated and/or regulatory
T cell populations that are pathogenic at the early
time point and protective at the late time point. We
now know that Foxp3 expression is not uniquely asso-
ciated with regulatory T cells [51,52]. We can
hypothesize that at the early time point, there is
a pathological population of activated cytotoxic
CD81 T lymphocytes. In support of this hypothesis,
D’Asaro et al. [53] reported a correlation between
increases in the effector memory subset (TEMRA,
CCR7–, CD45RA1) in CD81 T cells and the occur-
rence of cGVHDinpatientswho underwent allogeneic
PBSC transplantation. In addition, multiparous fe-
males have measurable levels of circulating HY, the
male-specific minor H antigen, and specific CD81
T cytotoxic lymphocytes can be readily expanded
in vitro. It is noteworthy that the use of multiparous
females as donors significantly increases the risk of
GVHD [54].
The discovery of temporally regulated cytokine
profiles in cGVHD has 2 potential applications that
merit further investigation. First, it is possible that cer-
tain cytokine expression levels could serve as
biomarkers in cGVHD. It is important that expression
levels of all of the cytokines discovered in this study be
applied prospectively to a new cohort of patients with
cGVHD to validate these cytokines as biomarkers.
This effort is currently under way. Cytokine expres-
sion can serve as a biomarker by (1) providing another
test to help confirm a diagnosis of cGVHDwhen there
is uncertainty; (2) directing the choice of therapy, that
is, choosing a therapy that targets pathogenic immune
subsets involved in the production of the cytokines;
and (3) determining whether a patient with cGVHD
is responding to therapy if cytokine levels change. Sec-
ond, determining the cells of origin of these cytokines
in future prospective studies will provide insight into
the pathophysiology of cGVHD.
Combiningourpreviousfindingswith thepresent re-
sults led us to generate a tentative model in which T cell
activationwith sIL2Ra and sBAFFup-regulation arepart
of early-onset cGVHD, and IFN-g and IL-2 production
is required to inhibit CD81 T cell and B cell expansion
and antibody production. Late-onset cGVHD is charac-
terized by a lack of Th2 shift and the development of
activated high TLR9–expressing B cells responding to
up-regulated BAFF expression from monocyte lineages.
TLR9 activation in combination with sBAFF results in
increased autoantibody production and makes these B
cells potent antigen-presenting cells for T cells in the pe-
riphery. IL-4 down-regulates TLR9 transcripts and pro-
teins in na€ıve B cells [55].
Data from the present study differ from that
reported previously. The present study involved
children and adolescents, and whether there are any
immunologic differences in cGVHD between these
1812 Biol Blood Marrow Transplant 17:1804-1813, 2011J. Rozmus et al.populations is unclear. Children have a lower incidence
of cGVHD compared with adults. Zecca et al. [56] re-
ported a cumulative probability of cGVHD of 27%,
less than one-half of the estimated probability in adults.
This was true even for children undergoing transplan-
tationwith bonemarrow stem cells, contesting the the-
ory that the overall incidence of cGVHD in children is
lower due to the increased use of cord blood stem cells.
It has been assumed that the mechanisms underlying
cGVHD are the same in children and adults as their
clinical manifestations, and that responses to therapy
are similar as well. Moreover, laboratory findings,
including sBAFF levels, are comparable in studies in-
volving both populations [10,15].
One possible limitation of the present study is that
both cyclosporin A and tacrolimus can have a potent
dose-dependent inhibitory effect on cytokine expression
from lymphocytes after stimulation with PI [57]. Puzik
et al. [57] reported that the effect of calcium calmodulin
inhibitors was dependent on donor age. In cord blood
lymphocytes, the inhibitory effect was dose-dependent,
whereas the function of adult lymphocytes was impaired
only at high doses of both compounds. In the present
study, the lack of statistical difference among the experi-
mental groups in terms of GVHD prophylaxis and cord
blood donors limits this confounding factor.
The cytokine expression results presented here pro-
vide novel evidence that there are potentially different
immune mechanisms underlying the timing of onset
of cGVHD. Furthermore, the different cytokine pro-
filesmay explain the numerous contradictions in the lit-
erature regarding cytokine expression and immune
dysregulation during cGVHD, particularly when the
timing of disease onset is not taken into account.ACKNOWLEDGMENTS
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